JINAL PATEL: Open Payments
NPI 1710464110 · GLASSBORO, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,020 in 54 payments from 11 companies in 2025. Trend: 2023 $752 · 2024 $896 · 2025 $1,020
Food & beverage: $915Education: $104
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $229 |
| Teva Pharmaceuticals USA, Inc. | 6 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $162 |
| Lundbeck LLC | 10 | $144 |
| E.R. Squibb & Sons, L.L.C. | 5 | $83 |
| Alkermes, Inc. | 4 | $67 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| ABBVIE INC. | 3 | $49 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: REXULTI, CAPLYTA, ABILIFY ASIMTUFII, AUSTEDO XR, COBENFY, Auvelity, VRAYLAR, ARISTADA.
Industry payments across NJ — which companies pay providers there.
